Business Wire

Boomi Introduces New Change Data Capture for SAP Data, Powering Agentic Transformation With Real-Time Insights

8.10.2025 10:00:00 CEST | Business Wire | Press Release

Share

Boomi, the leader in AI-driven automation, today announced the general availability of native Change Data Capture (CDC) ingestion for SAP data. Available globally today, the new capability enables enterprise teams to securely ingest data from SAP ECC, S/4HANA, and SAP Business Warehouse (BW) into any cloud data lake or warehouse without writing a single line of code. By making critical SAP data instantly accessible across the entire organization, this launch empowers organizations to act on insights faster, improve operational agility, and better support AI and analytics initiatives.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251008548992/en/

Boomi Introduces New Change Data Capture for SAP Data, Powering Agentic Transformation With Real-Time Insights

“This launch is a major milestone for SAP customers looking to modernize their data infrastructure,” said Mani Gill, VP of Product for Data and AI at Boomi. “By combining multi-table ingestion, built-in CDC, and schema-aware transformation, we’re unlocking SAP data for real-time decision-making without the need for specialist skills or custom development.”

With SAP customers generating 84% of total global commerce and 98 of the 100 largest companies in the world running on SAP1, the ability to easily access and act on SAP data is essential to driving innovation and operational efficiency. Boomi’s new CDC ingestion capability helps organizations modernize analytics without complexity — enabling SAP data to be ingested in minutes without the need for ABAP coding. By combining SAP and non-SAP data in real time, enterprises can accelerate time-to-insight for both AI and business intelligence use cases.

Unlike proprietary integration tools, Boomi offers flexibility and freedom of choice, allowing customers to feed data into any cloud data lake or warehouse, eliminating vendor lock-in. The solution also reduces cost and resource burdens by eliminating the need for custom SAP development and simplifying ongoing maintenance. Most importantly, it aligns with the demands of modern IT architectures, empowering enterprises to build scalable, cloud-native, and AI-driven data strategies for the future.

“Reliably extracting data from critical enterprise applications such as SAP to serve operational and analytical workloads has always been a technical challenge,” said Matt Aslett, Director of Research, Data and Analytics at ISG. “Products that reduce the complexity of accessing and acting on data are becoming foundational to improving business agility and supporting AI and analytics strategies at scale.”

Key Capabilities:

  • Built-in Change Data Capture (CDC): Captures changes in SAP ECC, S/4HANA, and BW in near real-time.
  • Multi-table ingestion: Ingests SAP data at scale from tables, CDS views, extractors, and more.
  • Schema-aware transformation: Converts raw SAP structured tabular data into JSON for easy and reliable data transfers.
  • SAP-certified, native application-layer integration: Boomi for SAP connects directly to SAP’s business logic via application layer — no database access required.
  • Enterprise features: Deduplication, stream checkpointing, and audit logging included.

Additional Resources:

About Boomi

Boomi, the leader in AI-driven automation, enables organizations worldwide to connect everything, automate processes, and accelerate outcomes. The Boomi Enterprise Platform — including Boomi Agentstudio — unifies integration and automation along with data, API, and AI agent management in a single, comprehensive solution. Trusted by over 25,000 customers and supported by a network of 800+ partners, Boomi is driving agentic transformation — helping enterprises of all sizes achieve agility, efficiency, and innovation at scale. Discover more at boomi.com.

© 2025 Boomi, LP. Boomi, the ‘Boomi’ logo, the ‘B’ logo, and Boomiverse are registered trademarks of Boomi, LP or its subsidiaries or affiliates in the US and other countries. All rights reserved. Other names or marks may be the trademarks of their respective owners.

_________________________

1 SAP, Fast Facts About SAP. https://www.sap.com/documents/2017/04/4666ecdd-b67c-0010-82c7-eda71af511fa.html

View source version on businesswire.com: https://www.businesswire.com/news/home/20251008548992/en/

Contacts

Media Contact:
Brandon Gubitosa
Data Management Media Relations & Communications
brandon.gubitosa@boomi.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye